Venetoclax and a Pediatric-Inspired Regimen for Newly Diagnosed B Cell Acute Lymphoblastic Leukemia
Phase 1
24
about 3.9 years
18–54
1 site in CA
About this study
This trial is testing the safety, side effects, and best dose of venetoclax in combination with a pediatric-inspired chemotherapy regimen called C10403 to treat patients with newly diagnosed B cell acute lymphoblastic leukemia. Venetoclax may stop cancer cells from growing by blocking Bcl-2, a protein needed for survival. The C10403 regimen includes several chemotherapy drugs that work in different ways to kill or prevent the growth of cancer cells, along with prednisone, an anti-inflammatory drug used to lower the body's immune response.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Cyclophosphamide
- 2.Take Cytarabine
- 3.Take Daunorubicin Hydrochloride
- +3 more
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
cyclophosphamide (Alkylating chemotherapy; crosslinks DNA strands), cytarabine, Antineoplastic Agent [TC] (DNA Polymerase Inhibitors), mercaptopurine, methotrexate, pegaspargase, prednisone, venetoclax
infusion, injection (Injection), oral (Oral Tablet), oral
Primary: Dose limiting toxicity, Incidence of adverse events
Secondary: Complete response (CR) after consolidation, Complete response (CR) after consolidation for Philadelphia (Ph)-like acute lymphoblastic leukemia (ALL), Complete response (CR) after induction +/- extended induction, Complete response (CR) after induction +/- extended induction for Philadelphia (Ph)-like acute lymphoblastic leukemia (ALL), Composite complete response (CR) (CR/ CR with incomplete hematologic recovery [CRi]/ CR with partial hematologic recovery [CRh]) after induction +/- extended induction, Composite complete response (CR) (CR/ CR with incomplete hematologic recovery [CRi]/ CR with partial hematologic recovery [CRh]) after induction +/- extended induction for Philadelphia (Ph)-like acute lymphoblastic leukemia (ALL), Overall survival
Oncology